City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy City Therapeutics, Inc., a biopharmaceutical leader in RNA interference (RNAi)-based medicine, has announced a strategic collaboration…
Free Testosterone Test: Revvity Receives FDA Clearance for First Automated Assay Revvity, Inc. (NYSE: RVTY), a global leader in health science solutions, has announced that it has received 510(k) clearance…
Pulse Biosciences Appoints Paul LaViolette as CEO Pulse Biosciences, Inc. (Nasdaq: PLSE), a leader in bioelectric medicine utilizing its cutting-edge Nanosecond Pulsed Field Ablation™ (nano-PFA™) technology, today announces the appointment…
Heidelberg Engineering’s ANTERION® Gets FDA Clearance for Epithelial Thickness Module Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, has announced the FDA clearance of its Epithelial…
Clinical Progress and Business Updates in Oncology Pipeline Reported by Nimbus Therapeutics Nimbus Therapeutics, a biotechnology company leveraging its advanced computational drug discovery engine to develop breakthrough medicines, today announced…
Reports Complete Response in First Infant with ECUR-506 for OTC Deficiency, iECURE iECURE, Inc., a gene-editing company focused on developing in vivo gene insertion therapies for liver disorders, reports promising…
Cofactor Genomics Announces CEO Change for Growth and OncoPrism Expansion Cofactor Genomics, Inc., a leader in precision medicine through RNA decoding, has appointed Chris Parker as CEO and Board Member…
Vir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500 Vir Biotechnology, Inc. (Nasdaq: VIR) has presented encouraging preliminary Phase 1 data from two of its dual-masked T-cell…
Phase 3 Studies for Azafaros Receive Key Regulatory Approvals, Set to Begin in 2025 Azafaros B.V. today revealed that its leading asset, nizubaglustat, has received Orphan Drug Designation (ODD) from…
Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C)…
Heart Failure Program and Leadership Change Announced by RyCarma RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma, is a clinical-stage biotech company focused on developing first-in-class small molecule therapeutics for…
Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences Castle Biosciences, Inc. (Nasdaq: CSTL), a leading company in providing innovative tests to guide patient care, has announced that its…